½ÃÀ庸°í¼­
»óǰÄÚµå
1389143

¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : À¯Çüº°, Á¦Ç°º° ¹× Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Digital Diabetes Management Market Size study & Forecast, by Type, by Product and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µðÁöÅÐ ´ç´¢º´ °ü¸®¶õ ¸ð¹ÙÀÏ ¾Û, ¿þ¾î·¯ºí ±â±â ¹× ±âŸ µðÁöÅÐ µµ±¸¿Í °°Àº µðÁöÅÐ ±â¼úÀ» »ç¿ëÇÏ¿© ´ç´¢º´ ȯÀÚÀÇ »óŸ¦ ¸ð´ÏÅ͸µ, °ü¸® ¹× °³¼±ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù.

´ç´¢º´Àº Àν¶¸° ºÐºñ°¡ ºÎÁ·Çϰųª Àν¶¸°À» È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ¾ø¾î °íÇ÷´çÀ» Ư¡À¸·Î ÇÏ´Â ¸¸¼º ´ë»ç ÁúȯÀÔ´Ï´Ù. µðÁöÅÐ ´ç´¢º´ °ü¸® ¼Ö·ç¼ÇÀº Ç÷´ç, ¾à¹°, ½Åü Ȱµ¿, ½Ä´ÜÀ» ÃßÀûÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ´Â µµ±¸¿Í ¸®¼Ò½º¸¦ Á¦°øÇÔÀ¸·Î½á ´ç´¢º´ ȯÀÚ°¡ ÀÚ°¡ °ü¸®¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÒ ¼ö ÀÖµµ·Ï µ½´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ´ç´¢º´ À¯º´·ü Áõ°¡, ´ç´¢º´ °ü¸®¸¦ À§ÇÑ Å¬¶ó¿ìµå ±â¹Ý ±â¾÷ ¼Ö·ç¼ÇÀÇ Ã¤Åà Ȯ´ë, ´ç´¢º´ °ü¸® ±â±âÀÇ ÀΰøÁö´É ÃâÇö, ´ç´¢º´ °ü¸®¸¦ À§ÇÑ µðÁöÅÐ Ç÷§ÆûÀÇ º¸±Þ°ú ¸ð¹ÙÀÏ ¾ÛÀÇ Ã¤Åà Áõ°¡·Î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¼¼°è ´ç´¢º´ À¯º´·üÀº ÁÖ·Î ÁÂ½Ä »ýȰ½À°ü, °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü, °í·ÉÈ­ µîÀ¸·Î ÀÎÇØ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ ¼ö°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ´ç´¢º´ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ±¹Á¦´ç´¢º´¿¬¸Í(IDF)¿¡ µû¸£¸é 2019³â 20-79¼¼ ¼ºÀÎ Áß 4¾ï 6,300¸¸ ¸í¿¡ °¡±î¿î »ç¶÷µéÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ±×¸®°í 2045³â¿¡´Â ¾à 7¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ¿¡ µû¶ó ´ç´¢º´ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´ °ü·Ã ÀÇ·á ÁöÃâ Áõ°¡¿Í e-Çコ äÅà Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ½ÅÈï °æÁ¦±¹ÀÇ ³·Àº äÅðú µ¥ÀÌÅÍ º¸¾ÈÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ´ç´¢º´ À¯º´·ü Áõ°¡, ÀÎÁöµµ ¹× ȯÀÚ Âü¿© Áõ°¡, ÀÇ·á ¹× ÀÎÇÁ¶ó ¼ºÀå, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ °ü½É Áõ°¡, Áö¿øÀûÀÎ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ 2022³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº e-Çコ µµÀÔ Áõ°¡, ´ç´¢º´ À¯º´·ü Áõ°¡, ÀÇ·á ÀÎ½Ä Áõ°¡, ÀÇ·áºñ Áõ°¡, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ µµÀÔ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°è ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ¿ªÇÐ

  • µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ
      • ´ç´¢º´ °ü·Ã ÀÇ·áºñ Áõ°¡
      • e-health µµÀÔ Áõ°¡

Á¦4Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çüº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çüº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ÇÚµåÇïµå µð¹ÙÀ̽º
    • ¿þ¾î·¯ºí µð¹ÙÀ̽º

Á¦6Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : Á¦Ç°º°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ
    • ½º¸¶Æ® Ç÷´çÃøÁ¤±â
    • ½º¸¶Æ® Àν¶¸° ÆßÇÁ
    • ½º¸¶Æ® Àν¶¸° Ææ
    • ¾Û

Á¦7Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, Áö¿ª ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • F. Hoffmann-La Roche Ltd.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Becton, Dickinson And Company
    • Bayer Ag
    • Acon Laboratories, Inc.
    • Medtronic Plc.
    • Novo Nordisk A/S
    • Terumo Corporation
    • Abbott Laboratories
    • Johnson And Johnson Limited
    • Dexcom, Inc

Á¦9Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH 23.12.15

Digital diabetes management refers to using digital technologies, such as mobile apps, wearable devices, and other digital tools, to help individuals with diabetes monitor, manage, and improve their condition. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to either inadequate insulin production or the body's inability to use insulin effectively. Digital diabetes management solutions aim to empower patients with diabetes to take an active role in their self-care by providing tools and resources to track and analyze their blood glucose levels, medication, physical activity, and diet. The key factors driving the market growth are the rising prevalence of diabetes, growing adoption of cloud-based enterprise solutions for diabetes management, the advent of artificial intelligence in diabetes care devices, and increasing penetration of digital platforms and adoption of mobile apps for diabetes management that anticipated to support the market growth during forecast period.

Moreover, the global prevalence of diabetes has been increasing steadily, primarily due to sedentary lifestyles, unhealthy diets, and an aging population. As the number of people with diabetes continues to rise, there is a growing need for efficient and scalable diabetes management solutions. For instance, as per the International Diabetic Federation (IDF), in 2019, there were nearly 463 million adults aged between 20-79 years were suffering from diabetes. Also, the amount is anticipated to reach around 700 million by 2045. As a result, the growing prevalence of diabetes is anticipated to support market growth. Additionally, increasing diabetes-related health expenditure and rising adoption of e-health are anticipated to create a lucrative opportunity for the market during the forecast period. However, the low adoption in developing economies and data security stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Digital Diabetes Management Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of diabetes, increasing awareness and patient engagement, growing healthcare and infrastructure, increasing focus on remote patient monitoring, and supportive reimbursement policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing adoption of e-health, increasing prevalence of diabetes, rising healthcare awareness, increasing healthcare expenditure, and growing adoption of telemedicine and remote monitoring.

Major market player included in this report are:

  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson And Company
  • Bayer Ag
  • Acon Laboratories, Inc.
  • Medtronic Plc
  • Novo Nordisk A/S
  • Terumo Corporation
  • Abbott Laboratories
  • Johnson And Johnson Limited
  • Dexcom, Inc

Recent Developments in the Market:

  • In September 2020, Roche Diagnostics (Switzerland) introduced a remote patient monitoring solution, that is an innovation of the RocheDiabetes Care Platform that utilises its pattern detection feature. These product launch helps to expand company product portfolio globally.

Global Digital Diabetes Management Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Product, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Handheld Devices
  • Wearable Devices

By Product:

  • Continuous blood glucose monitoring systems
  • Smart glucose meter
  • Smart insulin pumps
  • Smart insulin pens
  • Apps

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Digital Diabetes Management Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Digital Diabetes Management Market, by Type, 2020-2030 (USD Billion)
    • 1.2.3. Digital Diabetes Management Market, by Product, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Digital Diabetes Management Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Digital Diabetes Management Market Dynamics

  • 3.1. Digital Diabetes Management Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of diabetes
      • 3.1.1.2. Growing adoption of cloud-based enterprise solutions for diabetes management
      • 3.1.1.3. Advent of artificial intelligence in diabetes care devices
    • 3.1.2. Market Challenges
      • 3.1.2.1. Low adoption in developing economies and data security
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing diabetes-related health expenditure
      • 3.1.3.2. Rising adoption of e-health

Chapter 4. Global Digital Diabetes Management Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Digital Diabetes Management Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Digital Diabetes Management Market by Type, Performance - Potential Analysis
  • 5.3. Global Digital Diabetes Management Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 5.4. Digital Diabetes Management Market, Sub Segment Analysis
    • 5.4.1. Handheld Devices
    • 5.4.2. Wearable Devices

Chapter 6. Global Digital Diabetes Management Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Digital Diabetes Management Market by Product, Performance - Potential Analysis
  • 6.3. Global Digital Diabetes Management Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 6.4. Digital Diabetes Management Market, Sub Segment Analysis
    • 6.4.1. Continuous blood glucose monitoring systems
    • 6.4.2. Smart glucose meter
    • 6.4.3. Smart insulin pumps
    • 6.4.4. Smart insulin pens
    • 6.4.5. Apps

Chapter 7. Global Digital Diabetes Management Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Digital Diabetes Management Market, Regional Market Snapshot
  • 7.4. North America Digital Diabetes Management Market
    • 7.4.1. U.S. Digital Diabetes Management Market
      • 7.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Product breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Digital Diabetes Management Market
  • 7.5. Europe Digital Diabetes Management Market Snapshot
    • 7.5.1. U.K. Digital Diabetes Management Market
    • 7.5.2. Germany Digital Diabetes Management Market
    • 7.5.3. France Digital Diabetes Management Market
    • 7.5.4. Spain Digital Diabetes Management Market
    • 7.5.5. Italy Digital Diabetes Management Market
    • 7.5.6. Rest of Europe Digital Diabetes Management Market
  • 7.6. Asia-Pacific Digital Diabetes Management Market Snapshot
    • 7.6.1. China Digital Diabetes Management Market
    • 7.6.2. India Digital Diabetes Management Market
    • 7.6.3. Japan Digital Diabetes Management Market
    • 7.6.4. Australia Digital Diabetes Management Market
    • 7.6.5. South Korea Digital Diabetes Management Market
    • 7.6.6. Rest of Asia Pacific Digital Diabetes Management Market
  • 7.7. Latin America Digital Diabetes Management Market Snapshot
    • 7.7.1. Brazil Digital Diabetes Management Market
    • 7.7.2. Mexico Digital Diabetes Management Market
  • 7.8. Middle East & Africa Digital Diabetes Management Market
    • 7.8.1. Saudi Arabia Digital Diabetes Management Market
    • 7.8.2. South Africa Digital Diabetes Management Market
    • 7.8.3. Rest of Middle East & Africa Digital Diabetes Management Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. F. Hoffmann-La Roche Ltd.
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Becton, Dickinson And Company
    • 8.3.3. Bayer Ag
    • 8.3.4. Acon Laboratories, Inc.
    • 8.3.5. Medtronic Plc.
    • 8.3.6. Novo Nordisk A/S
    • 8.3.7. Terumo Corporation
    • 8.3.8. Abbott Laboratories
    • 8.3.9. Johnson And Johnson Limited
    • 8.3.10. Dexcom, Inc

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦